Oxford Science Enterprises
Oxford Science Enterprises (OSE) is an independent, permanent-capital Plc incorporated in 2015 with a partnership agreement granting preferred equity access to every University of Oxford scientific spinout across Life Sciences, HealthTech, and Deep Tech. A balance-sheet investor rather than a traditional LP fund structure, with no FCA AIFM registration, OSE has raised over GBP 850 million from more than 300 international investors including Google Ventures, Sequoia Capital, Tencent, Invesco, and Lansdowne Partners, and reports a balance sheet of around GBP 1.3 billion as of March 2026. The portfolio spans around 120 companies and has delivered landmark exits including Latent Logic to Waymo (2019), Base Genomics to Exact Sciences for USD 410 million (2020), MiroBio to Gilead for USD 405 million (2022), DJS Antibodies to AbbVie for USD 255 million (2022), Oxford Semantic Technologies to Samsung (2024), Oxford Ionics to IonQ for USD 1.075 billion (2025), and Dark Blue Therapeutics to Amgen for up to USD 840 million (2026). Ed Bussey has served as CEO since August 2023 and Jack Edmondson as CIO since September 2023. The firm is based in Oxford.
Key facts
Recent exits
Coverage notes
1 fund tracked, 59 portfolio companies (49 active · 10 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
59 companiesFunds & portfolio
Every fund Oxford Science Enterprises has raised, with its portfolio companies. Hand-checked from public filings.
Oxford Science Enterprises Balance SheetBalance Sheet2015 · 11yr€1.5B49 active · 10 realized
Unrealized
49 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  UK | 2025 | |
| AI/ML | UK | 2026 | |
| Biotech | UK | 2023 | |
| MedTech | UK | 2021 | |
| Biotech | UK | 2023 | |
| HealthTech | UK | 2018 | |
| Energy | UK | 2026 | |
| Biotech | UK | 2016 | |
| Deep Tech | UK | 2026 | |
| DevTools | UK | 2017 | |
| Mobility | UK | 2021 | |
| Biotech | UK | 2016 | |
| Energy | UK | 2011 | |
| ClimateTech | UK | 2022 | |
| Deep Tech | UK | 2024 | |
| HealthTech | UK | 2023 | |
| HealthTech | UK | 2025 | |
| HealthTech | UK | 2026 | |
| Biotech | UK | 2024 | |
| AI/ML | UK | 2016 | |
| AgTech | UK | 2019 | |
| ClimateTech | UK | 2025 | |
| ClimateTech | UK | 2023 | |
| Deep Tech | UK | 2022 | |
| Biotech | UK | 2019 | |
| HealthTech |  United States | 2025 | |
| Biotech | UK | 2016 | |
| Deep Tech | UK | 2017 | |
| Biotech | UK | 2016 | |
| Deep Tech | UK | 2019 | |
| Industrials | UK | 2015 | |
| Deep Tech | UK | 2016 | |
| Software | UK | 2020 | |
| Data & Analytics | UK | 2023 | |
| Deep Tech | UK | 2017 | |
| Deep Tech | UK | 2018 | |
| Deep Tech | UK | 2022 | |
| Biotech |  Netherlands | 2017 | |
| Biotech | UK | 2025 | |
| ClimateTech | UK | 2022 | |
| Biotech | UK | 2023 | |
| Energy | UK | 2023 | |
| Biotech | UK | 2017 | |
| Deep Tech | UK | 2026 | |
| Biotech | UK | 2021 | |
| Biotech | UK | 2025 | |
| Biotech | UK | 2017 | |
| HealthTech | UK | 2018 | |
| AgTech | UK | 2021 |
UK· Entry 2025UK· Entry 2026UK· Entry 2023UK· Entry 2021UK· Entry 2023UK· Entry 2018UK· Entry 2026UK· Entry 2016UK· Entry 2026UK· Entry 2017UK· Entry 2021UK· Entry 2016UK· Entry 2011UK· Entry 2022UK· Entry 2024UK· Entry 2023UK· Entry 2025UK· Entry 2026UK· Entry 2024UK· Entry 2016UK· Entry 2019UK· Entry 2025UK· Entry 2023UK· Entry 2022UK· Entry 2019United States· Entry 2025UK· Entry 2016UK· Entry 2017UK· Entry 2016UK· Entry 2019UK· Entry 2015UK· Entry 2016UK· Entry 2020UK· Entry 2023UK· Entry 2017UK· Entry 2018UK· Entry 2022Netherlands· Entry 2017UK· Entry 2025UK· Entry 2022UK· Entry 2023UK· Entry 2023UK· Entry 2017UK· Entry 2026UK· Entry 2021UK· Entry 2025UK· Entry 2017UK· Entry 2018UK· Entry 2021Realized
10 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | UK | 2018 | 2020 | Trade Sale | – | ||
| Energy | UK | 2016 | 2025 | Trade Sale | – | ||
| Biotech | UK | 2020 | 2026 | Trade Sale | – | ||
| Biotech | UK | 2016 | 2022 | Trade Sale | – | ||
| AI/ML | UK | 2017 | 2019 | Trade Sale | – | ||
| Biotech | UK | 2019 | 2022 | Trade Sale | – | ||
| Deep Tech | UK | 2019 | 2025 | Trade Sale | – | ||
| AI/ML | UK | 2017 | 2024 | Trade Sale | – | ||
| Biotech | United States | 2018 | 2022 | IPO | – | – | |
| Biotech | UK | 2016 | 2021 | IPO | – | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Oxford Science Enterprises
Oxford Science Enterprises (OSE) is the largest dedicated university venture investor in Europe with approximately £850 million raised cumulatively as of December 2024 (balance-sheet vehicle valued at approximately £1.1 billion), headquartered in Oxford. The firm was founded in 2015 as Oxford Sciences Innovation before rebranding to OSE in 2021, and operates as a partner-owned independent investment company (plc) and the preferred investor of the University of Oxford with exclusive first-look across Oxford spinouts. The evergreen balance-sheet vehicle is complemented by a $232 million bank facility (2023).
Investment thesis
OSE deploys capital through an evergreen balance-sheet structure (single vehicle) plus debt facility, targeting pre-seed to Series C venture capital investment for founding and scaling Oxford university spinouts. The evergreen capital structure enables unconstrained holding periods aligned with the long-duration scaling cycles typical of deep-tech and life sciences ventures. Sector focus spans life sciences, health tech, deep tech, biotech, therapeutics and AI, with a core portfolio of approximately 40 Oxford spinouts. Geographic deployment is anchored on the Oxford ecosystem with broader UK reach.
Recent activity
Recent investments include Beacon Therapeutics follow-on (gene therapy, 2026), Allos Global (2026) plus Cellular Origins and other deep-tech follow-ons across 2024-2025. Realised exits across 2024-2025 emphasised follow-on rounds rather than secondary realisations, with biotech exits forming the historical baseline and an uptick expected near-term. The platform continues active capital deployment across the Oxford spinout pipeline through the evergreen balance-sheet model. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
United Kingdom·€1.6B
United Kingdom·€1.4B
United Kingdom·€1.3B
United Kingdom·€1.7B
United Kingdom·€1.7B
United Kingdom·€1.3B
United Kingdom·€1.8B
United Kingdom·€1.8B
United Kingdom·€1.8B
United Kingdom·€1.2B
United Kingdom·€1.2B
United Kingdom·€1.2BGet the full picture on Oxford Science Enterprises.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in